Royalty Pharma plc Overview

Royalty Pharma plc Research & Development

Research & Development expenses for RPRX.

Quarterly R&D Expenses

$40.00M

↓ 20.79% YoY

As of Mar 31, 2026

Annual R&D Expenses (TTM)

$442.00M

↑ 733.96% YoY

Trailing 12 months ending Mar 31, 2026

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin